http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 25 Mar 2025 06:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Mar+25/24541998.html si-local-file:///var/storage/secattach/20250325/24541998.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Mar+25/24541998.html Tue, 25 Mar 2025 06:30:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Mar+25/24541998.html si-local-file:///var/storage/secattach/20250325/24541998.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Mar+25/24541998.html Tue, 25 Mar 2025 06:30:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++LakeShore+Biopharma+Co.%2C+++++++++++++/24501080.html si-local-file:///var/storage/secattach/20250314/24501080.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++LakeShore+Biopharma+Co.%2C+++++++++++++/24501080.html Fri, 14 Mar 2025 09:22:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++LakeShore+Biopharma+Co.%2C+++++++++++++/24501080.html si-local-file:///var/storage/secattach/20250314/24501080.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++LakeShore+Biopharma+Co.%2C+++++++++++++/24501080.html Fri, 14 Mar 2025 09:22:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Mar+12/24489088.html si-local-file:///var/storage/secattach/20250312/24489088.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Mar+12/24489088.html Wed, 12 Mar 2025 09:19:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Mar+12/24489088.html si-local-file:///var/storage/secattach/20250312/24489088.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Mar+12/24489088.html Wed, 12 Mar 2025 09:19:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Dec+19/24124715.html si-local-file:///var/storage/secattach/20241219/24124715.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Dec+19/24124715.html Thu, 19 Dec 2024 09:28:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Dec+19/24124715.html si-local-file:///var/storage/secattach/20241219/24124715.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Dec+19/24124715.html Thu, 19 Dec 2024 09:28:00 -0400 O.50653405 YS http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html <div class="xn-content"> <ul type="disc"><li><i>Achieved total revenue of <money>RMB 371.9 million</money>, reflecting a growth of 36.2% YoY</i></li><li><i>Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY</i></li><li><i>Gross margin increased to 82.6% from 80.9% in the same period of FY2024</i></li><li><i>Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY</i></li><li><i>Recorded net income of RMB 20.6 million, and adjusted net income^[1] (Non-GAAP) of <money>RMB 30.4 million</money>, compared to net loss and adjusted net loss^[1] (Non-GAAP) of <money>RMB 174.5 million</money> in the same period of FY2024</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Dec. 19, 2024</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd.</span> (Nasdaq: LSB) ("LakeShore" or http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Reports+Unaudited+Financial+Results+for+the+First+Half+of+Fiscal+Year+2025+and+Updates+Full-Year+Guidance/24124605.html Thu, 19 Dec 2024 09:05:00 -0400 A.19158983 LSB O.00159422 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Dec+12/24099739.html si-local-file:///var/storage/secattach/20241212/24099739.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Dec+12/24099739.html Thu, 12 Dec 2024 16:10:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Dec+12/24099739.html si-local-file:///var/storage/secattach/20241212/24099739.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Dec+12/24099739.html Thu, 12 Dec 2024 16:10:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+12/23959664.html si-local-file:///var/storage/secattach/20241112/23959664.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+12/23959664.html Tue, 12 Nov 2024 09:25:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+12/23959664.html si-local-file:///var/storage/secattach/20241112/23959664.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+12/23959664.html Tue, 12 Nov 2024 09:25:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+07/23940194.html si-local-file:///var/storage/secattach/20241107/23940194.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+07/23940194.html Thu, 07 Nov 2024 08:16:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+07/23940194.html si-local-file:///var/storage/secattach/20241107/23940194.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+07/23940194.html Thu, 07 Nov 2024 08:16:00 -0400 O.50653405 YS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+01/23916340.html si-local-file:///var/storage/secattach/20241101/23916340.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Nov+01/23916340.html Fri, 01 Nov 2024 16:01:00 -0400 O.50653405 YS